Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non–Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy

Cho, Anna; Kranawetter, Beate; Untersteiner, Helena; Khalaveh, Farjad; Dorfer, Christian; Rössler, Karl; Zöchbauer‐Müller, Sabine; Gatterbauer, Brigitte; Hochmair, Maximilian; Frischer, Josa M.

doi:10.1016/j.wneu.2021.04.033

Cited by 11 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, NLR and LMR groups remained statistically significant independent prognostic factors, even after adjusting for IT or TT treatment. We have previously reported that the prognostic role of NLR is superior to PLR or LMR superior in radiosurgically treated NSCLC BM patients with concomitant IT or TT [24]. The current study confirms that NLR may represent the most important leucocyte-based ratio for radiosurgically treated BM patients.…”

Section: Discussionsupporting

confidence: 84%

“…As we and others have commented before, the ability to predict survival in cancer patients with simple and widely available prognostic scores is of clinical importance and may help to facilitate clinical decision making and appropriate stratification of future clinical trials [7,20,24]. Still, we would like to further comment, that, at our institution, patients in a palliative setting or with a high number of BM are regularly treated radiosurgically if any benefit from the treatment might be anticipated.…”

Section: Discussionmentioning

confidence: 91%

“…The median treatment volume was 0.6 cm 3 (0.1-29.0). The prescribed doses mainly targeted the 50% (45-90) isodose line, with a median prescription dose of 18 Gy (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)) and a median central dose of 32 Gy .…”

Section: Radiosurgical Techniquementioning

confidence: 99%

See 2 more Smart Citations

The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor

et al. 2021

Self Cite

View full text Add to dashboard Cite

Purpose To investigate the clinical value of the inflammation based prognostic scores for patients with radiosurgically treated brain metastases (BM) originating from non-pulmonary primary tumor (PT). Methods A retrospective analysis of 340 BM patients of different PT origin (melanoma, breast, gastrointestinal, or genitourinary cancer) was performed. Pre-radiosurgical laboratory prognostic scores, such as the Neutrophil-to-Lymphocyte Ratio (NLR), the Platelet-to-Lymphocyte Ratio (PLR), Lymphocyte-to-Monocyte Ratio (LMR), and the modified Glasgow Prognostic Score (mGPS), were investigated within 14 days before the first Gamma Knife radiosurgical treatment (GKRS1). Results In our study cohort, the estimated survival was significantly longer in patients with NLR < 5 (p < 0.001), LMR > 4 (p = 0.001) and in patients with a mGPS score of 0 (p < 0.001). Furthermore, univariate and multivariate Cox regression models revealed NLR ≥ 5, LMR < 4 and mGPS score ≥ 1 as independent prognostic factors for an increased risk of death even after adjusting for age, sex, KPS, extracranial metastases status, presence of neurological symptoms and treatment with immunotherapy (IT) or targeted therapy (TT). Conclusions Summarizing previously published and present data, pre-radiosurgical mGPS and NLR groups seem to be the most effective and simple independent prognostic factors to predict clinical outcome in radiosurgically treated BM patients.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…We retrospectively analyzed a large consecutive cohort of LUAD patients’ laboratory tests for preNLR levels. We found that among those with BMs, high radio likely indicated a poor survival after surgery of BM in line with previous studies of brain metastasis ( P < 0.0001) [ 20 , 24 , 25 ]. On univariate analysis of overall survival, elevated preNLR was an independent prognostic poor factor along with KPS < 70, extracerebral metastases, age ≥ 65, without postoperative radiotherapy and targeted therapy.…”

Section: Discussionsupporting

confidence: 91%

Preoperative neutrophil-to-lymphocyte ratio (preNLR) for the assessment of tumor characteristics in lung adenocarcinoma patients with brain metastasis

Cui

Yang

Feng

et al. 2022

Translational Oncology

View full text Add to dashboard Cite

“…Common hematological indicators, such as inflammatory factors, tumor markers and cell free DNA (cfDNA) have gradually been shown to play important roles in the microenvironment of NSCLC. There is considerable evidence regarding neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in NSCLC patients treated with immunotherapy (11)(12)(13) and targeted therapy (14,15). However, few studies have explored the significance of these indicators in the alectinib treatment of ALK-positive NSCLC (16).…”

Section: What Is the Implication And What Should Change Now?mentioning

confidence: 99%

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

Jiang¹,

Shi²,

Liu³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Alectinib is a second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs), which has attracted much attention in the treatment of ALK-positive non-small cell lung cancer (NSCLC). At present, there are few reports on the efficacy and safety of alectinib in Chinese population. Moreover, biomarkers reflecting prognosis and efficacy are exceedingly needed. This study assessed the efficacy of alectinib in patients with ALK-positive NSCLC and analyzed the prognostic factors. Methods: Patients with ALK-positive NSCLC who were confirmed by histopathology or cytology at the Affiliated Cancer Hospital of Nanjing Medical University between October 2018 and October 2021 were enrolled. All patients were treated with alectinib. The clinical characteristics and circulating tumor biomarkers before and after treatment were collected. Kaplan-Meier test was used to calculate the progression-free survival (PFS). Univariate and multivariate Cox regression analyses were used to explore the influencing factors on PFS. Incidence of adverse events was observed. Results: Twenty patients progressed after first-line treatment (n=59) with alectinib, and 21 patients progressed following second-line treatment (n=36) with alectinib. The median PFS of first-line treatment patients was not achieved, and the median PFS of patients undergoing second-line treatment was 15.0 months ^ ORCID:

show abstract

Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non–Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy

Cited by 11 publications

References 27 publications

The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor

The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor

Preoperative neutrophil-to-lymphocyte ratio (preNLR) for the assessment of tumor characteristics in lung adenocarcinoma patients with brain metastasis

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

Contact Info

Product

Resources

About